Immunotherapy of head and neck cancer: current and future considerations.
Patients with head and neck squamous cell carcinoma (HNSCC) are at considerable risk for death, with 5-year relative survival rates of approximately 60%. The profound multifaceted deficiencies in cell-mediated immunity that persist in most patients after treatment may be related to the high rates of treatment failure and second primary malignancies. Radiotherapy and chemoradiotherapy commonly have severe acute and long-term side effects on immune responses. The development of immunotherapies reflects growing awareness that certain immune system deficiencies specific to HNSCC and some other cancers may contribute to the poor long-term outcomes. Systemic cell-mediated immunotherapy is intended to activate the entire immune system and mount a systemic and/or locoregional antitumor response. The delivery of cytokines, either by single cytokines, for example, interleukin-2, interleukin-12, interferon-gamma, interferon-alpha, or by a biologic mix of multiple cytokines, such as IRX-2, may result in tumor rejection and durable immune responses. Targeted immunotherapy makes use of monoclonal antibodies or vaccines. All immunotherapies for HNSCC except cetuximab remain investigational, but a number of agents whose efficacy and tolerability are promising have entered phase 2 or phase 3 development.
Rapidis
Alexander D
AD
Department of Head and Neck Surgery, Greek Anticancer Institute, Saint Savvas Hospital, 171 Alexandras Avenue, 115 22 Athens, Greece.
Wolf
Gregory T
GT
Otolaryngol Clin North Am. 1985 Aug;18(3):367-88
3900876
Cancer Res. 2002 Sep 1;62(17):5049-57
12208760
Mod Pathol. 2005 Apr;18(4):485-94
15475932
Clin Cancer Res. 2000 Mar;6(3):979-86
10741724
Crit Rev Oral Biol Med. 2003;14(5):345-62
14530303
Cancer Immunol Immunother. 2006 Apr;55(4):451-8
16034562
Anticancer Drugs. 2006 Jan;17(1):1-12
16317284
Biochem Biophys Res Commun. 2004 Oct 8;323(1):156-62
15351715
Arch Otolaryngol Head Neck Surg. 1992 May;118(5):526-8
1571128
Biol Pharm Bull. 2007 Jan;30(1):150-6
17202676
Arch Otolaryngol Head Neck Surg. 1987 Nov;113(11):1200-6
3499156
Cancer Immunol Immunother. 2004 May;53(5):375-82
14634795
N Engl J Med. 2003 Jan 16;348(3):203-13
12529460
Cancer. 2002 Jul 1;95(1):90-7
12115321
Jpn J Clin Oncol. 2007 Feb;37(2):140-5
17255158
Oncol Rep. 2005 Jan;13(1):3-10
15583794
Hum Immunol. 2001 Apr;62(4):332-41
11295465
Clin Cancer Res. 2005 Feb 1;11(3):1010-20
15709166
Curr Opin Pharmacol. 2002 Aug;2(4):382-7
12127870
Cancer. 1993 Apr 1;71(7):2326-31
8453554
N Engl J Med. 2007 May 10;356(19):1944-56
17494927
Clin Cancer Res. 2000 Jul;6(7):2794-802
10914726
J Immunother. 2008 Nov-Dec;31(9):885-95
18832999
Curr Opin Oncol. 2005 May;17(3):212-7
15818163
J Nucl Med. 2005 Apr;46(4):620-33
15809485
Cancer Biol Ther. 2006 Dec;5(12):1624-31
17172816
Arch Otolaryngol Head Neck Surg. 2000 Oct;126(10):1225-31
11031409
Proc Natl Acad Sci U S A. 1997 Mar 4;94(5):1914-8
9050879
Rev Recent Clin Trials. 2008 Sep;3(3):156-66
18782074
Expert Opin Emerg Drugs. 2006 Sep;11(3):461-7
16939385
Arch Otolaryngol Head Neck Surg. 2005 Apr;131(4):304-7
15837897
J Biomed Sci. 2008 May;15(3):275-89
18392689
Anticancer Res. 2004 Mar-Apr;24(2B):973-9
15161052
J Natl Cancer Inst. 2000 May 3;92(9):709-20
10793107
J Immunother. 2007 Sep;30(6):624-33
17667526
Clin Cancer Res. 2004 Apr 15;10(8):2626-35
15102664
Int J Cancer. 1995 Oct 20;64(5):304-8
7591301
Adv Otorhinolaryngol. 2005;62:151-60
15608425
Br J Cancer. 2005 Apr 25;92(8):1341-8
15846296
J Clin Oncol. 2004 May 1;22(9):1646-54
15117987
Curr Oncol Rep. 2001 Jan;3(1):46-55
11123869
Arch Otolaryngol Head Neck Surg. 1990 Nov;116(11):1271-7
2122909
Cancer Res. 1992 Sep 1;52(17):4832-6
1324797
Int J Cancer. 2007 Nov 15;121(10):2181-91
17597103
J Immunother. 2004 Mar-Apr;27(2):124-35
14770084
Clin Exp Metastasis. 2000;18(2):155-61
11235991
J Clin Oncol. 2005 Feb 1;23(4):720-31
15613691
Clin Cancer Res. 2000 Jan;6(1):24-33
10656428
Laryngoscope. 2005 Mar;115(3):391-404
15744147
Curr Opin Oncol. 2001 May;13(3):183-8
11307062
Head Neck. 2008 Feb;30(2):251-61
18172882
Curr Oncol Rep. 2009 Mar;11(2):156-62
19216848
Cancer Res. 2003 Mar 15;63(6):1188-91
12649174
Cancer Res. 1997 Oct 15;57(20):4593-9
9377574
Arch Pathol Lab Med. 1998 May;122(5):447-54
9593347
N Engl J Med. 2008 Sep 11;359(11):1143-54
18784104
Cancer Res. 2005 Dec 1;65(23):11146-55
16322265
Cancer Biol Ther. 2006 Sep;5(9):1226-7
17021387
Int Immunopharmacol. 2003 Aug;3(8):1061-71
12860163
Clin Cancer Res. 2006 Nov 15;12(22):6737-47
17121894
Head Neck. 2006 May;28(5):462-70
16284974
Head Neck. 2003 Mar;25(3):198-209
12599287
FASEB J. 2005 May;19(7):780-2
15774576
Clin Adv Hematol Oncol. 2005 Feb;3(2):92-3
16166973
Chemotherapy. 2002 Sep;48(4):211-6
12218269
J Clin Oncol. 2005 Dec 10;23(35):8942-9
16204009
Nat Med. 1996 Oct;2(10):1096-103
8837607
Head Neck. 2003 Jun;25(6):457-63
12784237
Int Immunopharmacol. 2003 Aug;3(8):1083-91
12860165
J Cancer Res Clin Oncol. 2005 Sep;131(9):624-30
16044346
Br J Cancer. 1996 Jan;73(2):228-35
8546911
Laryngoscope. 2003 May;113(5):888-91
12792328
J Clin Oncol. 2006 Apr 10;24(11):1705-11
16549819
Important Adv Oncol. 1992;:93-109
1316312
Cancer. 2001 Jun 1;91(11):2136-47
11391595